CVRx (NASDAQ:CVRX – Get Free Report) had its price objective decreased by stock analysts at Cantor Fitzgerald to $2.00 in a research note issued on Friday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Cantor Fitzgerald‘s price objective points to a potential upside of 229.27% from the company’s current price.
CVRX has been the topic of a number of other reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CVRx in a report on Friday, October 30th. Lake Street Capital reduced their price target on shares of CVRx from $3.50 to $1.50 and set a “hold” rating for the company in a research report on Friday, November 6th. William Blair cut shares of CVRx from an “outperform” rating to a “market perform” rating in a research note on Friday, November 6th. Canaccord Genuity Group downgraded shares of CVRx from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $5.00 to $2.00 in a research report on Friday, November 6th. Finally, Wall Street Zen lowered shares of CVRx from a “sell” rating to a “strong sell” rating in a research note on Sunday. One investment analyst has rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $2.70.
Read Our Latest Stock Analysis on CVRx
CVRx Price Performance
CVRX stock opened at $0.61 on Friday. The business’s 50-day moving average is $1.85 and its two-hundred day moving average is $5.00. The company has a debt-to-equity ratio of 4.24, a current ratio of 6.80 and a quick ratio of 5.71. The firm has a market capitalization of $17.30 million, a P/E ratio of -0.30 and a beta of 0.81. CVRx has a 1 year low of $0.60 and a 1 year high of $10.28.
CVRx (NASDAQ:CVRX – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.02). CVRx had a negative return on equity of 208.45% and a negative net margin of 88.28%. The business had revenue of $13.83 million for the quarter, compared to analyst estimates of $13.93 million. Analysts anticipate that CVRx will post -2.04 earnings per share for the current fiscal year.
Institutional Investors Weigh In On CVRx
Hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its holdings in shares of CVRx by 7.4% in the 1st quarter. Bank of New York Mellon Corp now owns 38,542 shares of the company’s stock valued at $365,000 after purchasing an additional 2,649 shares in the last quarter. Deutsche Bank AG acquired a new stake in shares of CVRx in the second quarter valued at about $62,000. Renaissance Technologies LLC purchased a new stake in CVRx during the first quarter worth about $183,000. Bank of America Corp DE purchased a new stake in CVRx during the second quarter worth about $102,000. Finally, Jump Financial LLC boosted its holdings in CVRx by 26.0% during the third quarter. Jump Financial LLC now owns 97,673 shares of the company’s stock worth $171,000 after buying an additional 20,173 shares in the last quarter. Institutional investors and hedge funds own 75.27% of the company’s stock.
CVRx Company Profile
CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.
See Also
- Five stocks we like better than CVRx
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for CVRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx and related companies with MarketBeat.com's FREE daily email newsletter.
